It has been demonstrated that the inhibition of PPARG, one subtype of the peroxisome proliferator-activated receptor, could reverse the metabolic reprogramming of compensatory glutamine and further sensitize HCC cells to sorafenib (51). The gene discussed is PPARG; the disease is hepatocellular carcinoma.